Nickan Research Institute Immunopathologia Persa 2423-8015 5 1 2019 01 01 Anti-inflammatory effects of different statins in rheumatoid arthritis; a randomized double-blind controlled clinical trial e09 e09 10.15171/ipp.2019.09 EN Mansoor Karimifar https://orcid.org/0000-0003-4688-991X Mansour Salesi Rasoul Ghasemian Mozhgan Karimifar Ziba Farajzadegan Mohammad Gholamnezhad Journal Article 10.15171/ipp.2019.09 2019 01 03 2019 03 09 Introduction: Statin family drugs are lipid-lowering agents with anti-inflammatory effects. Objectives: The aim of our study was to evaluate anti-inflammatory effects of different statins in rheumatoid arthritis patients. Patients and Methods: Around 161 eligible subjects with rheumatoid arthritis were enrolled. They randomly were divided into three groups. The first group received 40 mg/daily atorvastatin, the second group received 40 mg/daily simvastatin, and the third group received placebo as control for six months. To calculate the disease activity, DAS-28 (Disease Activity Score 28) was used while VAS (visual analog scale) was used to assess the severity of pain in rheumatoid arthritis patients. DAS-28, erythrocyte sedimentation rates (ESR) and lipid profiles were assessed once for the baseline and then after three and six months of intervention. Data was analyzed by SPSS by a P value <0.05 which was set to be significant. Results: DAS-28 score in months 0, 3 and 6 in atorvastatin, simvastatin and placebo groups was (5.36 ± 1.02, 3.23±1.24 and 2.81±1.13), (5.29±0.87, 2.75±1.16 and 2.57±1.00) and (5.52±0.96, 3.90±1.10 and 3.87±1.52), respectively. Mean of DAS-28 score differences between placebo and atorvastatin groups was 0.6±0.16 (P<0.01); the score differences between simvastatin and placebo was 0.900±0.16 that was significant (P<0.01), however, the score differences was not significant between atorvastatin and simvastatin groups (P=0.261). Conclusion: Statins decrease inflammation in rheumatoid arthritis patients